Antibacterial activity of a 1,8-naphthyridine quinolone, PD 131628.
A new 1,8-naphthyridine quinolone antimicrobial, PD131628, was found to be as, or more active than ciprofloxacin or ofloxacin against Escherichia coli and considerably more active than the two 4-quinolone agents against staphylococci in terms of both MIC and OBC (the optimum bactericidal concentration, at which the rate of kill is greatest). In common with ciprofloxacin and ofloxacin, the rate of kill of PD131628 against Enterococcus faecalis was considerably slower than against the other three species tested. Bacterial protein synthesis, RNA synthesis and cell division were not required for the bactericidal activity of PD131628 against E. coli or the staphylococci, although the lethality of PD131628 in the absence of these activities was reduced.
Lewin
C S
CS
Department of Medical Microbiology, University of Edinburgh Medical School.
D000890:Anti-Infective Agents / Q000737:chemistry / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D004260:DNA Repair; D004269:DNA, Bacterial; D013293:Enterococcus faecalis / Q000187:drug effects / Q000235:genetics / Q000254:growth & development; D004926:Escherichia coli / Q000187:drug effects / Q000235:genetics / Q000254:growth & development; D024841:Fluoroquinolones; D006801:Humans; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D009287:Naphthyridines; D015363:Quinolones / Q000737:chemistry / Q000494:pharmacology*; D013014:SOS Response, Genetics; D013211:Staphylococcus aureus / Q000187:drug effects / Q000235:genetics / Q000254:growth & development; D013212:Staphylococcus epidermidis / Q000187:drug effects / Q000235:genetics / Q000254:growth & development
D000890:Anti-Infective Agents; D004269:DNA, Bacterial; D024841:Fluoroquinolones; D009287:Naphthyridines; D015363:Quinolones; C068217:PD 131628